Florina-Nicoleta Grigore

Florina-Nicoleta Grigore

Auto-generated profile, based on publicly available information

Florina-Nicoleta Grigore

University of Minnesota

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKasey R. Skinner
Kasey R. Skinner
TKTomoyuki Koga
Tomoyuki Koga
SMShunichiro Miki
Shunichiro Miki
RGRobert F. Gruener
Robert F. Gruener
FGFlorina-Nicoleta Grigore
Florina-Nicoleta Grigore
FFFrank B. Furnari
Frank B. Furnari
Diffuse midline glioma (DMG) is a leading cause of brain tumor death in children. In addition to hallmark H3.3K27M mutations, significant subsets also harbor alterations of other genes, such as TP53 and PDGFRA . Despite the prevalence of H3.3K27M, the results of clinical trials in DMG have been mixed, possibly due to the lack of models recapitulating its genetic heterogeneity. To address this gap, we developed human iPSC-derived tumor models harboring TP53 R248Q with or without heterozygous H3.3K27M and/or PDGFRA D842V overexpression. The combination of H3.3K27M and PDGFRA D842V resulted in more proliferative tumors when gene-edited neural progenitor (NP) cells were implanted into mouse brains compared to NP with either mutation alone. Transcriptomic comparison of tumors and their NP cells of origin identified conserved JAK/STAT pathway activation across genotypes as characteristic of malignant transformation. Conversely, integrated genome-wide epigenomic and transcriptomic analyses, as well as rational pharmacologic inhibition, revealed targetable vulnerabilities unique to the TP53 R248Q ; H3.3K27M; PDGFRA D842V tumors and related to their aggressive growth phenotype. These include AREG -mediated cell cycle control, altered metabolism, and vulnerability to combination ONC201/trametinib treatment. Taken together, these data suggest that cooperation between H3.3K27M and PDGFRA influences tumor biology, underscoring the need for better molecular stratification in DMG clinical trials.

28 May 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CDCharles Asher Day
Charles Asher Day
FGFlorina Grigore
Florina Grigore
FHFaruck L. Hakkim
Faruck L. Hakkim
ALAlyssa Langfald
Alyssa Langfald
SFSela Fadness
Sela Fadness
EHEdward H. Hinchcliffe
Edward H. Hinchcliffe
During the cell cycle, differential phosphorylation of select histone H3 serine/threonine residues regulates chromatin structure, necessary for both dynamic transcriptional control and proper chromosome segregation 1-2 . Histone H3.3 contains a highly conserved serine residue (Ser31) within its N-terminal tail that is unique to this variant. During interphase phosphorylation of Ser31 amplifies stimulation-induced transcription and is required for early metazoan development 3-6 . During mitosis Ser31 phosphorylation at the pericentromere supports proper chromosome segregation, albeit by unknown mechanisms 7-10 . H3.3 Ser31 is flanked by mutational sites that drive several human cancers, including pediatric gliomas 5-8 . This is typified by the H3.3 K27M mutation found in ∼80% of diffuse midline gliomas, which undergo epigenetic reprogramming in proliferative cells coordinate with loss of global H3 lysine 27 trimethylation (H3K27Me3) 11-14 . However, whether the K27M mutation influences the neighboring Ser31 phosphorylation and whether disrupting Ser31 phosphorylation plays a distinct role in driving gliomagenesis has not been tested. Here we show that H3.3 K27M mutant cells have reduced capacity for H3.3 Ser31 phosphorylation at the mitotic pericentromere, increased rates of chromosome missegregation, and impaired G 1 checkpoint responses to chromosome instability. CRISPR-reversion of K27M to wild-type restores phospho-Ser31 levels and suppresses chromosome segregation defects. CRISPR editing to introduce a non-phosphorylatable H3.3 S31A alone is sufficient to increase the frequency of chromosome missegregations. Finally, expression of H3.3 S31A in a PDGFβ-driven RCAS/TVA mouse model is sufficient to drive high grade gliomagenesis, generating diffuse tumors morphologically indistinguishable from those generated by H3.3 K27M expression. Importantly, this occurs without the loss of H3K27 triple methylation that is the hallmark of K27M tumors. Our results reveal that the H3.3 K27M mutation alters the neighboring Ser31 phosphorylation, and loss of proper H3.3 Ser31 phosphorylation contributes to the formation of diffuse midline gliomas.